中文名 | LOXIGLUMIDE |
英文名 | LOXIGLUMIDE |
别名 | 氯谷胺 |
英文别名 | CS-162 LOXIGLUMIDE LoxigluMide (CR1505) (+-)-4-((3,4-dichlorobenzoyl)amino)-5-((3-methoxypropyl)pentylamino)-5-oxope 5-[amyl(3-methoxypropyl)amino]-4-[(3,4-dichlorobenzoyl)amino]-5-keto-valeric acid 4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid 4-[(3,4-dichlorophenyl)carbonylamino]-5-[3-methoxypropyl(pentyl)amino]-5-oxo-pentanoic acid |
CAS | 107097-80-3 |
化学式 | C21H30Cl2N2O5 |
分子量 | 461.38 |
密度 | 1.233±0.06 g/cm3(Predicted) |
熔点 | 113-115℃ |
沸点 | 632.2±55.0 °C(Predicted) |
溶解度 | DMSO: ≥ 5 mg/mL |
酸度系数 | pKa ~5(at 25℃) |
存储条件 | 2-8°C |
外观 | 粉末 |
颜色 | white to beige |
体内研究 | The effects of pancreatic rest by oral administration of CCK-1 receptor antagonist Loxiglumide and pancreas stimulation are investigated via endogenous CCK release induced by po protease inhibitor camostat on the recovery of pancreatic secretory function, and biochemical and histological changes of the pancreas after acute hemorrhagic pancreatitis. Oral administration of CCK-1 receptor antagonist Loxiglumide with a dose of 50 mg/kg body weight inhibits pancreatic exocrine secretion for more than 12 h. Thus, every 12-h administration of Loxiglumide might have completely blocks the effect of endogenously released CCK on the pancreas (pancreatic rest). |
危险品标志 | Xn - 有害物品 |
风险术语 | 22 - 吞食有害。 |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.167 ml | 10.837 ml | 21.674 ml |
5 mM | 0.433 ml | 2.167 ml | 4.335 ml |
10 mM | 0.217 ml | 1.084 ml | 2.167 ml |
5 mM | 0.043 ml | 0.217 ml | 0.433 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!